Jacek Plichta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacek Plichta has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Michał Panek
Department of Internal Medicine, Asthma and Allergy Medical University of Lodz Lodz Poland
4 shared publicationsPiotr Kuna
Department of Internal Medicine, Asthma and Allergy Medical University of Lodz Lodz Poland
3 shared publications- Michał Panek
Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, 90-419 Lodz, Poland
2 shared publications - Piotr Kuna
Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland
2 shared publications - Aleksandra Wisniewska
Department of Clinical Pharmacology, Ist Chair of Internal Medicine, Medical University of Lodz, 90-153 Lodz, Poland
1 shared publication Alicja Majos
Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, 90‑153 Lodz, Poland
1 shared publication
Latest Publications
- Open Access
- 29 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5217
Asthma and COPD Beyond the Airways: Exploring Neurocognitive Links Through NF-κB Subunits c-Rel and p65
The evolving understanding of asthma and COPD pathomechanisms led to this study examining chronic obstructive lung diseases’ impact on cognitive decline—a growing concern in aging populations. We explored whether subunits of key inflammatory regulators NF-κB, c-Rel (neuroprotective), and p65 (neurodegenerative), are linked to cognitive impairment. A pilot study with an explorative design across three groups (asthma, COPD, and control) included 78 patients. Participants underwent assessments via 16 questionnaires (covering demographics, quality of life, disease control, and cognitive and psychiatric evaluations), spirometry, and blood sampling to measure c-Rel and p65 mRNA expression. While both c-Rel and p65 are NF-κB subunits, their expression levels differ independently. Median c-Rel expression was highest, and p65 lowest, in the group with the best cognitive function (control). The most notable correlations for both markers with PKA, CREB, MMSE, and HAM-D were in COPD. The significant association between p65 and the Clock-Drawing Test, without a corresponding link to MMSE, may indicate that a future correlation between p65 and cognitive decline, as assessed by CDT, is likely to emerge.
- 29 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5217
Open AccessAsthma and COPD Beyond the Airways: Exploring Neurocognitive Links Through NF-κB Subunits c-Rel and p65
The evolving understanding of asthma and COPD pathomechanisms led to this study examining chronic obstructive lung diseases’ impact on cognitive decline—a growing concern in aging populations. We explored whether subunits of key inflammatory regulators NF-κB, c-Rel (neuroprotective), and p65 (neurodegenerative), are linked to cognitive impairment. A pilot study with an explorative design across three groups (asthma, COPD, and control) included 78 patients. Participants underwent assessments via 16 questionnaires (covering demographics, quality of life, disease control, and cognitive and psychiatric evaluations), spirometry, and blood sampling to measure c-Rel and p65 mRNA expression. While both c-Rel and p65 are NF-κB subunits, their expression levels differ independently. Median c-Rel expression was highest, and p65 lowest, in the group with the best cognitive function (control). The most notable correlations for both markers with PKA, CREB, MMSE, and HAM-D were in COPD. The significant association between p65 and the Clock-Drawing Test, without a corresponding link to MMSE, may indicate that a future correlation between p65 and cognitive decline, as assessed by CDT, is likely to emerge.
- Open Access
- 17 April 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (8) , e70548
In Silico–Designed TGFβRI/TGFβRII Receptor Complex Peptide Inhibitors Exhibit Biological Activity In Vitro
TGF‐β (transforming growth factor β) is a pleiotropic cytokine found in three isoforms in humans. It regulates cell proliferation, wound healing, immune cell recruitment, contributes to epithelial‐to‐mesenchymal transition (EMT) and to the conversion of fibroblasts to myofibroblasts. TGF‐β signalling pathway hyperactivity underlies many human disorders. The aim of this study was to evaluate a series of novel, in silico–designed peptide inhibitors (PIs) of the TGFβ/TGFβRI/TGFβRII complex. Luciferase‐based luminescence assays on HEK293T cells were used to comparatively assess PI biological activity and calculate IC50 values. Flow cytometry was used to assess PI cytotoxicity on HEK293T cells. The PIs caused significant luminescence level reductions compared to controls. Additionally, three of the PIs caused luminescence reductions that did not differ significantly from the effects of SD‐208, a small molecule TGFβ inhibitor. None of the PIs exhibited cytotoxicity. Our TGFBR PIs have demonstrated activity in vitro, with no observed cytotoxicity. Our results suggest the PIs may be of interest in the treatment of fibrotic disorders, chronic inflammatory diseases, or certain neoplastic cancers. The PIs will be further refined in silico and tested via assays carried out on cancer cell lines and CD4+/CD8+ T cells.
- 17 April 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (8) , e70548
Open AccessIn Silico–Designed TGFβRI/TGFβRII Receptor Complex Peptide Inhibitors Exhibit Biological Activity In Vitro
TGF‐β (transforming growth factor β) is a pleiotropic cytokine found in three isoforms in humans. It regulates cell proliferation, wound healing, immune cell recruitment, contributes to epithelial‐to‐mesenchymal transition (EMT) and to the conversion of fibroblasts to myofibroblasts. TGF‐β signalling pathway hyperactivity underlies many human disorders. The aim of this study was to evaluate a series of novel, in silico–designed peptide inhibitors (PIs) of the TGFβ/TGFβRI/TGFβRII complex. Luciferase‐based luminescence assays on HEK293T cells were used to comparatively assess PI biological activity and calculate IC50 values. Flow cytometry was used to assess PI cytotoxicity on HEK293T cells. The PIs caused significant luminescence level reductions compared to controls. Additionally, three of the PIs caused luminescence reductions that did not differ significantly from the effects of SD‐208, a small molecule TGFβ inhibitor. None of the PIs exhibited cytotoxicity. Our TGFBR PIs have demonstrated activity in vitro, with no observed cytotoxicity. Our results suggest the PIs may be of interest in the treatment of fibrotic disorders, chronic inflammatory diseases, or certain neoplastic cancers. The PIs will be further refined in silico and tested via assays carried out on cancer cell lines and CD4+/CD8+ T cells.
- Open Access
- 30 January 2025
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 6, 1529071
Role of the TGF-β cytokine and its gene polymorphisms in asthma etiopathogenesis
Transforming growth factor beta (TGF-β) is a pluripotent cytokine expressed by all cells of the human body which plays important roles in maintaining homeostasis and allowing for proper individual development. Disturbances in TGF-β signaling contribute to the development of many diseases and disorders, including cancer and organ fibrosis. One of the diseases with the best-characterized correlation between TGF-β action and etiopathogenesis is asthma. Asthma is the most common chronic inflammatory disease of the lower and upper respiratory tract, characterized by bronchial hyperresponsiveness to a number of environmental factors, leading to bronchospasm and reversible limitation of expiratory flow. TGF-β, in particular TGF-β1, is a key factor in the etiopathogenesis of asthma. TGF-β1 concentration in bronchoalveolar lavage fluid samples is elevated in atopic asthma, and TGF-β expression is increased in asthmatic bronchial samples. The expression of all TGF-β isoforms is affected by a number of single nucleotide polymorphisms found in the genes encoding these cytokines. Some of the SNPs that alter the level of TGF-β expression may be associated with the occurrence and severity of symptoms of asthma and other diseases. The TGF-β gene polymorphisms, which are the subject of this paper, are potential diagnostic factors. If properly used, these polymorphisms can facilitate the early and precise diagnosis of asthma, allowing for the introduction of appropriate therapy and reduction of asthma exacerbation frequency.
- 30 January 2025
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 6, 1529071
Open AccessRole of the TGF-β cytokine and its gene polymorphisms in asthma etiopathogenesis
Transforming growth factor beta (TGF-β) is a pluripotent cytokine expressed by all cells of the human body which plays important roles in maintaining homeostasis and allowing for proper individual development. Disturbances in TGF-β signaling contribute to the development of many diseases and disorders, including cancer and organ fibrosis. One of the diseases with the best-characterized correlation between TGF-β action and etiopathogenesis is asthma. Asthma is the most common chronic inflammatory disease of the lower and upper respiratory tract, characterized by bronchial hyperresponsiveness to a number of environmental factors, leading to bronchospasm and reversible limitation of expiratory flow. TGF-β, in particular TGF-β1, is a key factor in the etiopathogenesis of asthma. TGF-β1 concentration in bronchoalveolar lavage fluid samples is elevated in atopic asthma, and TGF-β expression is increased in asthmatic bronchial samples. The expression of all TGF-β isoforms is affected by a number of single nucleotide polymorphisms found in the genes encoding these cytokines. Some of the SNPs that alter the level of TGF-β expression may be associated with the occurrence and severity of symptoms of asthma and other diseases. The TGF-β gene polymorphisms, which are the subject of this paper, are potential diagnostic factors. If properly used, these polymorphisms can facilitate the early and precise diagnosis of asthma, allowing for the introduction of appropriate therapy and reduction of asthma exacerbation frequency.
- Open Access
- 1 October 2024
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 28 (6) , 1-14
Nasal allergen and methacholine provocation tests influence co‑expression patterns of TGF‑β/SMAD and MAPK signaling pathway genes in patients with asthma
Asthma is characterized by chronic bronchial inflammation and is a highly heterogeneous disease strongly influenced by both specific and non‑specific exogenous factors. The present study was performed to assess the effect of nasal allergen provocation tests and methacholine provocation tests on the mRNA co‑expression patterns of genes (SMAD1/3/6/7, MPK1/3 and TGFB1/3) involved in SMAD and non‑SMAD TGF‑β signaling pathways in patients with asthma. Reverse transcription‑quantitative PCR was performed on blood samples taken pre‑provocation and 1 h post‑provocation to assess gene expression changes. Of the 59 patients studied, allergen provocations were administered to 27 patients and methacholine provocations to 32 patients. Correlations between expression levels of studied genes were found to be influenced markedly by the challenge administered, challenge test result and time elapsed since challenge. Importantly, increases in expression levels for four gene pairs (MAPK1‑SMAD3, MAPK3‑SMAD3, SMAD1‑SMAD3 and SMAD3‑TGFB1) were found to correlate significantly with asthma occurrence in the allergen provocation cohort, but not in the methacholine provocation cohort. The present study allows us to draw the conclusion that both intranasal allergen and bronchial methacholine challenges influence mRNA co‑expression patterns of the SMAD1/3/6/7, MPK1/3 and TGFB1/3 genes.
- 1 October 2024
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 28 (6) , 1-14
Open AccessNasal allergen and methacholine provocation tests influence co‑expression patterns of TGF‑β/SMAD and MAPK signaling pathway genes in patients with asthma
Asthma is characterized by chronic bronchial inflammation and is a highly heterogeneous disease strongly influenced by both specific and non‑specific exogenous factors. The present study was performed to assess the effect of nasal allergen provocation tests and methacholine provocation tests on the mRNA co‑expression patterns of genes (SMAD1/3/6/7, MPK1/3 and TGFB1/3) involved in SMAD and non‑SMAD TGF‑β signaling pathways in patients with asthma. Reverse transcription‑quantitative PCR was performed on blood samples taken pre‑provocation and 1 h post‑provocation to assess gene expression changes. Of the 59 patients studied, allergen provocations were administered to 27 patients and methacholine provocations to 32 patients. Correlations between expression levels of studied genes were found to be influenced markedly by the challenge administered, challenge test result and time elapsed since challenge. Importantly, increases in expression levels for four gene pairs (MAPK1‑SMAD3, MAPK3‑SMAD3, SMAD1‑SMAD3 and SMAD3‑TGFB1) were found to correlate significantly with asthma occurrence in the allergen provocation cohort, but not in the methacholine provocation cohort. The present study allows us to draw the conclusion that both intranasal allergen and bronchial methacholine challenges influence mRNA co‑expression patterns of the SMAD1/3/6/7, MPK1/3 and TGFB1/3 genes.
- Open Access
- 2 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1207641
Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives
Chronic inflammatory diseases of the lung are some of the leading causes of mortality and significant morbidity worldwide. Despite the tremendous burden these conditions put on global healthcare, treatment options for most of these diseases remain scarce. Inhaled corticosteroids and beta-adrenergic agonists, while effective for symptom control and widely available, are linked to severe and progressive side effects, affecting long-term patient compliance. Biologic drugs, in particular peptide inhibitors and monoclonal antibodies show promise as therapeutics for chronic pulmonary diseases. Peptide inhibitor-based treatments have already been proposed for a range of diseases, including infectious disease, cancers and even Alzheimer disease, while monoclonal antibodies have already been implemented as therapeutics for a range of conditions. Several biologic agents are currently being developed for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and pulmonary sarcoidosis. This article is a review of the biologics already employed in the treatment of chronic inflammatory pulmonary diseases and recent progress in the development of the most promising of those treatments, with particular focus on randomised clinical trial outcomes.
- 2 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1207641
Open AccessBiologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives
Chronic inflammatory diseases of the lung are some of the leading causes of mortality and significant morbidity worldwide. Despite the tremendous burden these conditions put on global healthcare, treatment options for most of these diseases remain scarce. Inhaled corticosteroids and beta-adrenergic agonists, while effective for symptom control and widely available, are linked to severe and progressive side effects, affecting long-term patient compliance. Biologic drugs, in particular peptide inhibitors and monoclonal antibodies show promise as therapeutics for chronic pulmonary diseases. Peptide inhibitor-based treatments have already been proposed for a range of diseases, including infectious disease, cancers and even Alzheimer disease, while monoclonal antibodies have already been implemented as therapeutics for a range of conditions. Several biologic agents are currently being developed for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and pulmonary sarcoidosis. This article is a review of the biologics already employed in the treatment of chronic inflammatory pulmonary diseases and recent progress in the development of the most promising of those treatments, with particular focus on randomised clinical trial outcomes.
- Open Access
Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
The COVID-19 pandemic continues to cause tremendous loss of life and put massive strain on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral outbreak, as of yet, no effective curative treatment is available. COVID-19 vaccines, while effective and a scientific achievement of historical proportions, can only be utilized in prophylaxis and require vaccination of the majority of a given population. Convalescent plasma therapies require blood group testing and patient hospitalization and are difficult to put into place in the scale of a population. Monoclonal antibodies can be mass produced with hybridoma cell culture and are highly specific to viral antigens. What is more, monoclonal antibodies produce far more reproducible effects than other approaches to active immunization and can be further enhanced through engineering. Currently, there exist two approaches to COVID-19 treatment with use of monoclonal antibodies, each with several antibodies currently under development or in clinical testing. The first of the approaches utilizes monoclonal antibodies, which target viral spike proteins to block viral entry into host cell and mark viral particles for destruction by host immune cells. The second approach utilizes antibodies that neutralize cytokines, which take part in cytokine release syndrome, which is responsible for many of the most damaging symptoms associated with COVID-19, thus reducing systemic inflammation and ultimately—patient morbidity and mortality. There yet remain several challenges to overcome if monoclonal antibodies are to become mainstream therapeutic agents in the treatment of COVID-19. Despite this, this field of research is experiencing a massive forward leap and the exceptional amount of clinical data gathered so far can serve as groundwork for the development of effective and widely available antiviral monoclonal antibody treatments.
Open AccessMonoclonal Antibodies as Potential COVID-19 Therapeutic Agents
The COVID-19 pandemic continues to cause tremendous loss of life and put massive strain on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral outbreak, as of yet, no effective curative treatment is available. COVID-19 vaccines, while effective and a scientific achievement of historical proportions, can only be utilized in prophylaxis and require vaccination of the majority of a given population. Convalescent plasma therapies require blood group testing and patient hospitalization and are difficult to put into place in the scale of a population. Monoclonal antibodies can be mass produced with hybridoma cell culture and are highly specific to viral antigens. What is more, monoclonal antibodies produce far more reproducible effects than other approaches to active immunization and can be further enhanced through engineering. Currently, there exist two approaches to COVID-19 treatment with use of monoclonal antibodies, each with several antibodies currently under development or in clinical testing. The first of the approaches utilizes monoclonal antibodies, which target viral spike proteins to block viral entry into host cell and mark viral particles for destruction by host immune cells. The second approach utilizes antibodies that neutralize cytokines, which take part in cytokine release syndrome, which is responsible for many of the most damaging symptoms associated with COVID-19, thus reducing systemic inflammation and ultimately—patient morbidity and mortality. There yet remain several challenges to overcome if monoclonal antibodies are to become mainstream therapeutic agents in the treatment of COVID-19. Despite this, this field of research is experiencing a massive forward leap and the exceptional amount of clinical data gathered so far can serve as groundwork for the development of effective and widely available antiviral monoclonal antibody treatments.